JP2019516707A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516707A5
JP2019516707A5 JP2018560460A JP2018560460A JP2019516707A5 JP 2019516707 A5 JP2019516707 A5 JP 2019516707A5 JP 2018560460 A JP2018560460 A JP 2018560460A JP 2018560460 A JP2018560460 A JP 2018560460A JP 2019516707 A5 JP2019516707 A5 JP 2019516707A5
Authority
JP
Japan
Prior art keywords
fibromyalgia
general formula
group
alkyl
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018560460A
Other languages
English (en)
Japanese (ja)
Other versions
JP7071287B2 (ja
JP2019516707A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2017/005173 external-priority patent/WO2017200318A1/ko
Publication of JP2019516707A publication Critical patent/JP2019516707A/ja
Publication of JP2019516707A5 publication Critical patent/JP2019516707A5/ja
Application granted granted Critical
Publication of JP7071287B2 publication Critical patent/JP7071287B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018560460A 2016-05-19 2017-05-18 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用 Active JP7071287B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160061392 2016-05-19
KR10-2016-0061392 2016-05-19
PCT/KR2017/005173 WO2017200318A1 (ko) 2016-05-19 2017-05-18 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Publications (3)

Publication Number Publication Date
JP2019516707A JP2019516707A (ja) 2019-06-20
JP2019516707A5 true JP2019516707A5 (enExample) 2020-06-25
JP7071287B2 JP7071287B2 (ja) 2022-05-18

Family

ID=60325216

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018560460A Active JP7071287B2 (ja) 2016-05-19 2017-05-18 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用

Country Status (14)

Country Link
US (1) US10849882B2 (enExample)
EP (1) EP3459543B1 (enExample)
JP (1) JP7071287B2 (enExample)
KR (1) KR102489052B1 (enExample)
CN (1) CN109475529B (enExample)
AU (1) AU2017265839B2 (enExample)
BR (1) BR112018073553A2 (enExample)
CA (1) CA3024286A1 (enExample)
DK (1) DK3459543T3 (enExample)
ES (1) ES2935596T3 (enExample)
MX (1) MX394245B (enExample)
PL (1) PL3459543T3 (enExample)
RU (1) RU2753525C2 (enExample)
WO (1) WO2017200318A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7086076B2 (ja) * 2016-12-14 2022-06-17 エスケー バイオファーマスティカルズ カンパニー リミテッド 振戦又は振戦症候群の予防、軽減又は治療のためのカルバメート化合物の使用
US11666554B2 (en) * 2017-11-14 2023-06-06 Sk Biopharmaceuticals Co., Ltd. Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease
US11406620B2 (en) * 2017-11-14 2022-08-09 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing or treating diseases associated with increase in late sodium current
JP7258901B2 (ja) 2017-11-14 2023-04-17 エスケー バイオファーマスティカルズ カンパニー リミテッド 欠神発作又は欠神発作を示すてんかんの予防、軽減又は治療のためのカルバメート化合物の使用
TWI837197B (zh) * 2018-10-19 2024-04-01 南韓商愛思開生物製藥股份有限公司 胺基甲酸酯化合物於預防、緩解或治療糖尿病周邊神經病變或化療誘發的周邊神經病變的用途
KR20220104746A (ko) * 2019-11-22 2022-07-26 에스케이바이오팜 주식회사 카바메이트 화합물을 포함하는 경구용 약제학적 조성물 및 그 제조방법
IT202300007314A1 (it) 2023-04-14 2024-10-14 Soal Pharma Srl Integratore alimentare per il trattamento della fibromialgia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
CN101669933A (zh) * 2001-07-16 2010-03-17 奥索-麦克尼尔药品公司 用于预防或治疗神经性疼痛和丛集性头痛及偏头痛性疼痛的氨基甲酸酯化合物
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
WO2010150946A1 (en) * 2009-06-22 2010-12-29 Sk Holdings Co., Ltd. Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) * 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
KR101783633B1 (ko) * 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 섬유근육통 증후군의 치료 방법

Similar Documents

Publication Publication Date Title
JP2019516707A5 (enExample)
RU2494095C2 (ru) Модифицированные миметики лизина
JP2016512531A5 (enExample)
JP2015532295A5 (enExample)
JP2020519661A5 (enExample)
JP2018524298A5 (enExample)
JP2015528471A5 (enExample)
RU2015143610A (ru) Лечение катаплексии
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2014511892A5 (enExample)
RU2018144785A (ru) Применение соединения карбаминовой кислоты для профилактики или лечения фибромиалгии или функционального синдрома, ассоциированного с фибромиалгией
JP2016518437A5 (enExample)
JP2016509047A5 (enExample)
JP2012530779A5 (enExample)
JP2015024998A5 (enExample)
RU2009116455A (ru) Применение индуцирующих гипотермию лекарственных средств для лечения ишемии
JP2013509441A5 (enExample)
JP2019516739A5 (enExample)
JP2012520321A5 (enExample)
RU2011147186A (ru) 2, 5-дизамещенные арилсульфонамидные антагонисты ссr3
JP2019516726A5 (enExample)
BRPI0618522A2 (pt) diaril uréia para o tratamento de hipertensão pulmonar
FI3506900T3 (fi) Ampreloksetiini käytettäväksi neurogeenisen ortostaattisen hypotension
JP2016537432A5 (enExample)
JP2019516722A5 (enExample)